Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Delcath Systems has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Delcath Systems Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
GuruFocus does not calculate Delcath Systems's interest coverage with the available data.
Delcath Systems's debt to revenue ratio for the quarter that ended in Jun. 2026 was 0.02.
As of today, Delcath Systems's Altman Z-Score is 17.98.
Delcath Systems (NAS:DCTH) Financial Strength Explanation
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Delcath Systems has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Delcath Systems Financial Strength Related Terms
DCTH vs CERS, CTKB, TCMD: Financial Strength Comparison
For the Medical Devices subindustry, Delcath Systems's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delcath Systems Financial Strength vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Financial Strength distribution charts can be found below:
* The bar in red indicates where Delcath Systems's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
GuruFocus does not calculate Delcath Systems's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Delcath Systems Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Delcath Systems's Debt to Revenue Ratio for the quarter that ended in Jun. 2026 is
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Delcath Systems has a Z-score of 17.98, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 17.98 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Delcath Systems (DCTH) has a Financial Strength of 8 as of Jun. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Delcath Systems and its competitors. This is 167% above median its historical median of 3.00. Over the past decade, Delcath Systems' Financial Strength has ranged from 1.00 to 9.00.
Is Delcath Systems' Financial Strength too high?
Delcath Systems' current Financial Strength of 8 is 167% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Delcath Systems has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' Financial Strength compare to CERS and CTKB?
Delcath Systems' Financial Strength of 8 can be compared against companies in the Medical Devices & Instruments industry. Historically, Delcath Systems' own Financial Strength has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Medical Devices & Instruments company?
A good Financial Strength depends on the Medical Devices & Instruments industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Delcath Systems and its competitors. Delcath Systems's current Financial Strength is 8, which is 167% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $29.61, compared to a current price of $16.48 — trading 44.4% below its estimated fair value. The current Financial Strength is 8, which is 167% above median its 10-year median of 3.00. Delcath Systems' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Delcath Systems (DCTH), the current Financial Strength is 8 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delcath Systems (DCTH) Overvalued in 2026?
Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued.
The current stock price of $16.48 is trading 44.4% below its estimated GF Value™ of $29.61.
GuruFocus considers Delcath Systems to be Significantly Undervalued.
Key valuation signals for DCTH:
Financial Strength: 8 (167% above median its 10-year median of 3.00)
GF Value™: $29.61 vs. price of $16.48 (44.4% below fair value)
No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
77GF Score
Get the complete analysis for DCTH
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCTH has been successfully added to your 
